Eli Lilly raises 2026 outlook again as Q2 soars past estimates

Thursday, August 6, 2026Robert BarrieView original

Reporting 91% growth for Mounjaro, Lilly widened the gap to cardiometabolic rival Novo Nordisk.

Read the full article on the original site.